(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network!. Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

SEC Charges Former Army Financial Counselor Who Defrauded Gold Star Family Members

July 07th, 2023

FOR IMMEDIATE RELEASE 2023-127 Washington D.C. / CRWE PRESS RELEASE / July 7, 2023 - The Securities and Exchange Commission today charged former U.S. Army financial counselor Caz L. Craffy for defrauding Gold Star family members and others b. Read more

Earnings Reaction: AZZ Disappoints; $5.25M Order Fuels Alpine 4

July 07th, 2023

AZZ Inc. (NYSE: AZZ) reported first-quarter fiscal 2024 earnings per share (EPS) of $1.14 and sales of $390.87 million, slightly below the consensus EPS of $1.16 on revenue of $396.65 million. Despite the earnings results, the company is. Read more

Market Movers: ZyVersa and Castle Biosciences Share the Spotlight

July 07th, 2023

Shares of ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) surged over 20% in early trade after the European Patent Office granted a patent (number EP 2 836 221) for its Cholesterol Efflux Mediator VAR 200 in the treatment of diabetic nephropathy/diabetic k. Read more

Morgan Stanley's Bullish Stance: Ford, General Motors, and Ferrari

July 07th, 2023

Ford Motor Company (NYSE: F), a renowned automobile manufacturer, was maintained with an Overweight rating by Morgan Stanley, who raised the price target from $14 to $16. Based on Thursday's closing price of $14.98, the adjusted price target indic. Read more

LEQEMBI Breakthrough: FDA Approves Eisai and Biogen's Alzheimer's Therapy

July 07th, 2023

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more

Lockheed Martin Lands Lucrative Contracts Worth $136M+

July 07th, 2023

Lockheed Martin Corporation (NYSE: LMT) has secured two significant contracts with a combined value of $136,102,558. The first contract is a $122,706,700 cost-plus-fixed-fee modification to an existing contract. This modification focuses on critic. Read more

Cronos Group Gains Ground on Potential Transaction, Gorilla Technology Seals $270M+ 3Y-Deal

July 06th, 2023

Shares of Cronos Group Inc. (Nasdaq: CRON) experienced a surge of over 5% in the extended session after confirming receipt of several unsolicited indications of interest from third parties, signaling potential transactions involving Cronos and these . Read more

FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval

July 06th, 2023

Action Follows Confirmatory Trial to Verify Clinical Benefit Silver Spring, MD / CRWE PRESS RELEASE / July 06, 2023 -   Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult p. Read more

Breaking: Levi Strauss Lowers Outlook, AbbVie Reveals EPS Impact

July 06th, 2023

Levi Strauss & Co. (NYSE: LEVI) has released its financial results for the second quarter of 2023. The company reported earnings per share (EPS) of $0.04, slightly exceeding the consensus estimate of $0.03. However, net revenues for the quarter were . Read more

Market Surge: Mullen Gains Momentum, Pfizer's Investment Fuels Caribou Biosciences

July 06th, 2023

Shares of Mullen Automotive, Inc. (Nasdaq: MULN) surged over 60% in pre-market trading after the company announced a $25 million stock buyback program authorized through December 31, 2023. Mullen believes that its stock is significantly undervalue. Read more